Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

What Is Oligometastatic Prostate Cancer?

Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, Corcoran NM, Hovens CM, Tran PT, Ost P, Boutros PC; GAP6 Consortium.

Eur Urol Focus. 2019 Jan 11. pii: S2405-4569(18)30411-5. doi: 10.1016/j.euf.2018.12.009. [Epub ahead of print] Review.

PMID:
30642810
2.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

3.

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.

Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM.

Nat Rev Urol. 2017 Jan;14(1):15-25. doi: 10.1038/nrurol.2016.175. Epub 2016 Oct 11. Review.

4.

Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.

Joice GA, Rowe SP, Pienta KJ, Gorin MA.

Curr Opin Urol. 2017 Nov;27(6):533-541. doi: 10.1097/MOU.0000000000000449. Review.

PMID:
28863016
5.

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.

Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, Deroose CM, Goffin K, Herrmann K, Hoekstra OS, Kramer G, Lievens Y, Lopci E, Pasquier D, Petersen LJ, Talbot JN, Zacho H, Tombal B, deSouza NM.

Lancet Oncol. 2018 Oct;19(10):e534-e545. doi: 10.1016/S1470-2045(18)30571-0. Epub 2018 Oct 1. Review.

PMID:
30303127
6.

Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.

Larbi A, Dallaudière B, Pasoglou V, Padhani A, Michoux N, Vande Berg BC, Tombal B, Lecouvet FE.

Prostate. 2016 Aug;76(11):1024-33. doi: 10.1002/pros.23196. Epub 2016 May 16.

PMID:
27197649
7.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

8.

Oligometastatic prostate cancer: Reality or figment of imagination?

Foster CC, Weichselbaum RR, Pitroda SP.

Cancer. 2019 Feb 1;125(3):340-352. doi: 10.1002/cncr.31860. Epub 2018 Dec 6. Review.

PMID:
30521067
9.

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.

Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, Beckers A, Fonteyne V, Van der Eecken K, De Bruycker A, Paul J, Gramme P, Ost P.

World J Urol. 2018 Dec 21. doi: 10.1007/s00345-018-2609-8. [Epub ahead of print]

PMID:
30578441
10.

Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer.

Stephens SJ, Moravan MJ, Salama JK.

J Oncol Pract. 2018 Jan;14(1):23-31. doi: 10.1200/JOP.2017.026500.

PMID:
29324212
11.

Risk stratification in oligometastatic prostate cancer: where are we and what do we need?

Morgans AK, Hussain M.

Curr Opin Urol. 2017 Nov;27(6):547-552. doi: 10.1097/MOU.0000000000000439. Review.

PMID:
28825922
12.

Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.

De Bleser E, Tran PT, Ost P.

Curr Opin Urol. 2017 Nov;27(6):587-595. doi: 10.1097/MOU.0000000000000441. Review.

PMID:
28816714
13.

Chemotherapy for oligometastatic prostate cancer.

Dorff TB, Sweeney CJ.

Curr Opin Urol. 2017 Nov;27(6):553-558. doi: 10.1097/MOU.0000000000000446. Review.

PMID:
28817399
14.

[Surgical treatment of local disease in metastatic prostate cancer.]

Gaya JM, Huguet J, Breda A, Palou J.

Arch Esp Urol. 2018 Mar;71(3):288-297. Review. Spanish.

PMID:
29633950
15.

Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.

Clement JM, Sweeney CJ.

J Oncol Pract. 2017 Jan;13(1):9-18. doi: 10.1200/JOP.2016.018523. Epub 2017 Jan 3. Review.

PMID:
28045610
16.

Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs.

Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR.

Clin Exp Metastasis. 2014 Aug;31(6):735-48. doi: 10.1007/s10585-014-9664-3. Epub 2014 Jun 27. Review.

17.

Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.

Koo KC, Dasgupta P.

Yonsei Med J. 2018 Jul;59(5):567-579. doi: 10.3349/ymj.2018.59.5.567. Review.

18.

The oligometastatic state in breast cancer: hypothesis or reality.

Tait CR, Waterworth A, Loncaster J, Horgan K, Dodwell D.

Breast. 2005 Apr;14(2):87-93. Review.

PMID:
15767177
19.

[Radiotherapy for local disease in metastatic prostate cancer.]

Cambeiro M, Calvo FA.

Arch Esp Urol. 2018 Mar;71(3):298-305. Review. Spanish.

PMID:
29633951
20.

Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.

Juan O, Popat S.

Clin Lung Cancer. 2017 Nov;18(6):595-606. doi: 10.1016/j.cllc.2017.03.002. Epub 2017 Mar 14. Review.

Supplemental Content

Support Center